186 related articles for article (PubMed ID: 9000127)
1. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
4. Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs.
Hecker D; Page G; Lohrum M; Weiland S; Scheidtmann KH
Oncogene; 1996 Mar; 12(5):953-61. PubMed ID: 8649812
[TBL] [Abstract][Full Text] [Related]
5. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner.
Haapajärvi T; Kivinen L; Heiskanen A; des Bordes C; Datto MB; Wang XF; Laiho M
Exp Cell Res; 1999 Apr; 248(1):272-9. PubMed ID: 10094833
[TBL] [Abstract][Full Text] [Related]
6. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
[TBL] [Abstract][Full Text] [Related]
7. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
8. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
9. GADD34 induces p53 phosphorylation and p21/WAF1 transcription.
Yagi A; Hasegawa Y; Xiao H; Haneda M; Kojima E; Nishikimi A; Hasegawa T; Shimokata K; Isobe K
J Cell Biochem; 2003 Dec; 90(6):1242-9. PubMed ID: 14635196
[TBL] [Abstract][Full Text] [Related]
10. p53 phosphorylation mutants retain transcription activity.
Fuchs B; O'Connor D; Fallis L; Scheidtmann KH; Lu X
Oncogene; 1995 Feb; 10(4):789-93. PubMed ID: 7862459
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
12. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
13. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo.
Jamal S; Ziff EB
Oncogene; 1995 Jun; 10(11):2095-101. PubMed ID: 7784054
[TBL] [Abstract][Full Text] [Related]
14. Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53.
Tarapore P; Tokuyama Y; Horn HF; Fukasawa K
Oncogene; 2001 Oct; 20(47):6851-63. PubMed ID: 11687964
[TBL] [Abstract][Full Text] [Related]
15. The apoptotic and transcriptional transactivation activities of p53 can be dissociated.
Bissonnette N; Wasylyk B; Hunting DJ
Biochem Cell Biol; 1997; 75(4):351-8. PubMed ID: 9493957
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
17. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes.
Thornborrow EC; Patel S; Mastropietro AE; Schwartzfarb EM; Manfredi JJ
Oncogene; 2002 Feb; 21(7):990-9. PubMed ID: 11850816
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage.
Dohoney KM; Guillerm C; Whiteford C; Elbi C; Lambert PF; Hager GL; Brady JN
Oncogene; 2004 Jan; 23(1):49-57. PubMed ID: 14712210
[TBL] [Abstract][Full Text] [Related]
20. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
